Vertex Pharmaceuticals EBIT

The latest EBIT for VRTX is $5.1B as of June 2026. That compares with $4.2B in the prior-year period — up 20.9% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Vertex Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, VRTX's EBIT moved from $4.2B to $5.1B — a 20.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vertex Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, VRTX currently prints $5.1B for EBIT, while the sector average sits near $110B. That is roughly 95.3% below the sector mean. Large gaps often invite a closer look at Vertex Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $5.1B for VRTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting VRTX's EBIT ($5.1B), review year-over-year change from $4.2B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.